AMRI has merged its Discovery R&D and Discovery Chemistry departments to form a Global Drug Discovery organization. Bruce J. Sargent, Ph.D., has been appointed senior vice president of the new organization. The company is combining its discovery chemistry and biology functions into a single unit across locations worldwide.

“AMRI has been involved in numerous integrated discovery projects for a number of years,” said Dr. Sargent. “Our experience in successfully developing projects both internally and in collaboration with customers stands as a testament to our ability to provide a high level of project management, well developed and tested solutions, and added-value to our customers.”

“Customers are increasingly seeking out CROs that can provide them with fully integrated solutions in their pursuit to diminish costs and project timelines, while still desiring to maintain a high level of quality and value,” said chairman, chief executive officer and president Thomas E. D’Ambra, Ph.D. “We believe that combining all of our discovery capabilities in biology and discovery chemistry under the direction of Dr. Sargent will further enhance AMRI’s ability to generate significant value for our customers and stakeholders.”